APA (7th ed.) Citation

Pointreau, Y., Larnaudie, A., Sun, X., Rolland, F., Boisselier, P., Tao, Y., . . . Bourhis, J. (2026). Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin. Radiotherapy & Oncology, 219, N.PAG. https://doi.org/10.1016/j.radonc.2026.111479

Chicago Style (17th ed.) Citation

Pointreau, Y., A. Larnaudie, X.S Sun, F. Rolland, P. Boisselier, Y. Tao, C. Hugo, and J. Bourhis. "Discontinuation of the Double-blind, Placebo-controlled Randomized, Phase III GORTEC 2022–01 Trial of Radiotherapy-cetuximab and Xevinapant in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Unfit for Cisplatin." Radiotherapy & Oncology 219 (2026): N.PAG. https://doi.org/10.1016/j.radonc.2026.111479.

MLA (9th ed.) Citation

Pointreau, Y., et al. "Discontinuation of the Double-blind, Placebo-controlled Randomized, Phase III GORTEC 2022–01 Trial of Radiotherapy-cetuximab and Xevinapant in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Unfit for Cisplatin." Radiotherapy & Oncology, vol. 219, 2026, p. N.PAG, https://doi.org/10.1016/j.radonc.2026.111479.